Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo

Gynecologic Oncology

Volumn 109, Issue 1, 2008, Pages 97-106

  Taylor, Stacey A ^a   Marrinan, Cindy H ^a   Liu, Gongjie ^a   Nale, Lissette ^a   Bishop, W Robert ^a   Kirschmeier, Paul ^a   Liu, Ming ^a   Long, Brian J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Farnesyltransferase inhibitor; Lonafarnib; Ovarian cancer; Paclitaxel

Indexed keywords

CASPASE 3; LONAFARNIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FARNESYLTRANSTRANSFERASE; FEMALE; HSP40 HEAT-SHOCK PROTEINS; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, NUDE; MICE, SCID; OVARIAN NEOPLASMS; PACLITAXEL; PIPERIDINES; PYRIDINES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 40949114590     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.12.013     Document Type: Article

References (29)

1. Holschneider C.H., and Berek J.S. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19 (2000) 3-10
2. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer; three year results. J Natl Cancer Inst 92 (2000) 699-708
3. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21 (2003) 3194-3200
4. Jemel A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
5. Basso A.D., Kirschmeier P., and Bishop W.R. Thematic review series: lipid posttranslational modifications: farnesyl transferase inhibitors. J Lipid Res 47 (2006) 15-31
6. Zhang F.L., Kirschmeier P., Carr D., James L., Bond R.W., Wang L., et al. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 272 (1997) 10232-10239
7. Whyte D.B., Kirschmeier P., Hockenberry T.N., Nunez-Oliva I., James L., Catino J.J., et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272 (1997) 14459-14464
8. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Li Z., et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58 (1998) 4947-4956
9. Nielsen L.L., Shi B., Hijian G., Yaremko B., Lipari P., Ferrari E., et al. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. Cancer Res 59 (1999) 5896-5901
10. Moasser M.M., Sepp-Lorenzino L., Kohl N.E., Oliff A., Balog A., Su D.S., et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 95 (1998) 1369-1374
11. Shi B., Yaremko B., Hajian G., Terracina G., Bishop W.R., Liu M., et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 46 (2000) 387-393
12. Basso A.D., Mirza A., Liu G., Long B.J., Bishop W.R., and Kirschmeier P. The FTI SCH66336 (Lonafarnib) inhibits Rheb farnesylation and mTOR signaling: role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem 280 (2005) 31101-31108
13. Adjei A.A., Davis J.N., Erlichman C., Svingen P.A., and Kaufmann S.H. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6 (2000) 2318-2325
14. Njoroge F.G., Taveras A.G., Kelly J., Remiszewski S., Mallams A.K., Wolin R., et al. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J Med Chem 41 (1998) 4890-4902
15. Liu G., Marrinan C.H., Taylor S.A., Black S., Basso A.D., Kirschmeier P., et al. Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336). Anti-cancer Drugs 18 (2007) 923-932
16. Ashar H.R., James L., Gray K., Carr D., McGuirk M., Maxwell E., et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2)/M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res 262 (2001) 17-27
17. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R11577 in vivo and in vitro. Cancer Res 61 (2001) 131-137
18. Moasser M.M., and Rosen N. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. Breast Cancer Res Treat 73 (2002) 135-144
19. Nakamura K., Yamaguchi A., Namiki M., Ishihara H., Nagasu T., Kowalczyk J.J., et al. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel. Oncol Res 12 (2001) 477-484
20. Zhu K., Gerbino E., Beaupre D.M., Mackley P.A., Muro-Cacho C., Beam C., et al. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 105 (2005) 4759-4766
21. Khuri F.R., Glisson B.S., Kim E.S., Statkevich P., Thall P.F., Meyers M.L., et al. Phase I study of farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10 (2004) 2968-2976
22. Rossner D., Hollwitz B., Schaff C., Ay A., Rinnau F., Lersch W., et al. The combination of paclitaxel and the farnesyltransferase inhibitor SCH 66336 in the treatment of metastatic breast cancer. A phase I/II study. Proc 27th Annual San Antonio Breast Cancer Symposium (2004) Abstract 1068
23. Kim E.S., Kies M.S., Fossella F.V., Glisson B.S., Zaknoen S., Statkevich P., et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104 (2005) 561-569
24. Ready N.E., Lipton A., Zhu Y., Statkevich P., Frank E., Curtis D., et al. Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. Clin Cancer Res 13 (2007) 576-583
25. Bailey H.H., Alberti D.B., Thomas J.P., Mulkerin D.L., Binger K.A., Gottardis M.M., et al. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. Clin Cancer Res 13 (2007) 3623-3629
26. Ashar H.R., James L., Gray K., Carr D., Black S., Armstrong L., et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275 (2000) 30451-304517
27. Schafer-Hales K., Iaconelli J., Snyder J.P., Prussia A., Nettles J.H., El-Naggar A., et al. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 6 (2007) 1317-1328
28. Marcus A.I., Zhou J., O'Brate A., Hamel E., Wong J., Nivens M., et al. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 65 (2005) 3883-3893
29. Agarwal R., and Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 3 (2003) 502-516